drugset / Trial / NCT05821777
A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors
Phase 1/2
Terminated
25 enrolled
Centessa Pharmaceuticals (UK) Limited
LockBody Therapeutics Ltd · collab
NaSequentialOpen-labelTreatment
Summary
The purpose of this study is to assess safety, tolerability, and preliminary activity of LB101 monotherapy in participants with advanced solid tumors.
Timeline
- Start
- 2023-03-28
- Primary completion
- 2025-01-24
- Completion
- 2025-09-09
Outcome
Outcome not reported
Stopped: “Sponsor terminated the study due to non-safety reasons. Based on the data and the current competitive landscape, Sponsor made the decision to close the study.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LB101 | Unknown | — | Intravenous |